GCP
MLYS icon

GSA Capital Partners’s Mineralys Therapeutics MLYS Stock Holding History

GSA Capital Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48,401
Closed -$655K – 1928
2025
Q2 		$655K Buy
48,401
+33,113
+217% +$480K 0.05% 739
2025
Q1 		$243K Buy
+15,288
New +$176K 0.02% 1288

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSA Capital Partners's MLYS Position: Q3 2025 in Review

GSA Capital Partners sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 48,401 shares — an estimated $655K sold.

GSA Capital Partners first reported a position in MLYS in Q1 2025 and held it in 2 quarters. The position peaked at $655K in Q2 2025. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • GSA Capital Partners reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 48,401 Mineralys Therapeutics shares in Q3 2025, an estimated $655K.
  • GSA Capital Partners first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 2 quarters.
  • GSA Capital Partners's Mineralys Therapeutics position peaked at $655K in Q2 2025.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.